Daniel M. Halperin

Daniel M. Halperin

Auto-generated profile, based on publicly available information

Daniel M. Halperin

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ADArvind Dasari
Arvind Dasari
CSChan Shen
Chan Shen
DHDaniel Halperin
Daniel Halperin
BZBo Zhao
Bo Zhao
SZShouhao Zhou
Shouhao Zhou
JYJames C. Yao
James C. Yao
Given the rarity and indolent clinical course of neuroendocrine tumors (NETs), the epidemiology of these tumors is best studied in large, population-based registries with considerable longitudinal follow-up.1-3 The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program is a comprehensive source of population-based information initiated in 1973 that is updated annually.4,5 Previously, the most comprehensive population-based study of NETs in the United States had been performed by our group using the November 2006 submission of SEER data with cases diagnosed up to 2004 that showed increasing incidence.1 Since then, the SEER Program has expanded and the current (SEER 18) registry grouping now includes approximately 30% of the US population. Diagnostic techniques for NETs, such as computed tomography and endoscopy, have improved and have likely increased NET diagnosis rates and accuracy of staging.6-8 In addition, updated staging and grading classifications for NETs have been proposed and more universally adopted, possibly further increasing the recognition of NETs and improving their pathologic classification.9-11 Based on these observations, we hypothesized that the increased incidence of NETs is associated mainly with the rise in detection of early-stage disease.

3 September 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LULuis Ulloa
Luis Ulloa
MOMahendar Ochani
Mahendar Ochani
HYHuan Yang
Huan Yang
MTMahira Tanovic
Mahira Tanovic
DHDaniel Halperin
Daniel Halperin
KTKevin J. Tracey
Kevin J. Tracey
Sepsis, a potentially fatal clinical syndrome, is mediated by an early (e.g., tumor necrosis factor and IL-1) and late [e.g., high mobility group B-1 (HMGB1)] proinflammatory cytokine response to infection. Specifically targeting early mediators has not been effective clinically, in part because peak mediator activity often has passed before therapy can be initiated. Late-acting downstream effectors, such as HMGB1, that mediate sepsis lethality may be more relevant therapeutic targets. Ethyl pyruvate (EP) recently was identified as an experimental therapeutic that significantly protects against lethal hemorrhagic shock. Here, we report that EP attenuates lethal systemic inflammation caused by either endotoxemia or sepsis even if treatment begins after the early tumor necrosis factor response. Treatment with EP initiated 24 h after cecal puncture significantly increased survival (vehicle survival = 30% vs. EP survival = 88%, P < 0.005). EP treatment significantly reduced circulating levels of HMGB1 in animals with established endotoxemia or sepsis. In macrophage cultures, EP specifically inhibited activation of p38 mitogen-activated protein kinase and NF-κB, two signaling pathways that are critical for cytokine release. This report describes a new strategy to pharmacologically inhibit HMGB1 release with a small molecule that is effective at clinically achievable concentrations. EP now warrants further evaluation as an experimental “rescue” therapeutic for sepsis and other potentially fatal systemic inflammatory disorders.

1 April 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
DHDaniel M Halperin
Daniel M Halperin
CSChan Shen
Chan Shen
ADArvind Dasari
Arvind Dasari
YXYing Xu
Ying Xu
YCYiyi Chu
Yiyi Chu
JYJames C Yao
James C Yao

1 June 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
APAlexandria T Phan
Alexandria T Phan
DHDaniel M Halperin
Daniel M Halperin
JCJennifer A Chan
Jennifer A Chan
DFDavid R Fogelman
David R Fogelman
KHKenneth R Hess
Kenneth R Hess
MKMatthew H Kulke
Matthew H Kulke

14 July 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KRKanwal Raghav
Kanwal Raghav
SLSuyu Liu
Suyu Liu
MOMichael J. Overman
Michael J. Overman
AWAnneleis F. Willett
Anneleis F. Willett
MKMark Knafl
Mark Knafl
DHDaniel M. Halperin
Daniel M. Halperin
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade (AtezoBev) was assessed in 20 patients with advanced and unresectable MPeM with progression or intolerance to prior platinum–pemetrexed chemotherapy. The primary endpoint of confirmed objective response rate per RECISTv1.1 by independent radiology review was 40% [8/20; 95% confidence interval (CI), 19.1–64.0] with median response duration of 12.8 months. Six (75%) responses lasted for >10 months. Progression-free and overall survival at one year were 61% (95% CI, 35–80) and 85% (95% CI, 60–95), respectively. Responses occurred notwithstanding low tumor mutation burden and PD-L1 expression status. Baseline epithelial–mesenchymal transition gene expression correlated with therapeutic resistance/response (r = 0.80; P = 0.0010). AtezoBev showed promising and durable efficacy in patients with advanced MPeM with an acceptable safety profile, and these results address a grave unmet need for this orphan disease. Significance: Efficacy of atezolizumab and bevacizumab vis-à-vis response rates and survival in advanced peritoneal mesothelioma previously treated with chemotherapy surpassed outcomes expected with conventional therapies. Biomarker analyses uncovered epithelial–mesenchymal transition phenotype as an important resistance mechanism and showcase the value and feasibility of performing translationally driven clinical trials in rare tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659

1 October 2017 in Pancreas
Verified
Journal Article
Closed access
RNReza Nejati
Reza Nejati
JGJennifer B. Goldstein
Jennifer B. Goldstein
DHDaniel M. Halperin
Daniel M. Halperin
HWHua Wang
Hua Wang
NHNazila Hejazi
Nazila Hejazi
HWHuamin Wang
Huamin Wang
Objectives: The aim of this study was to examine tumor-infiltrating lymphocytes (TILs) and their prognostic value in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy.Methods: Intratumoral CD4+, CD8+, and FOXP3+lymphocytes were examined by immunohistochemistry using a computer-assisted quantitative analysis in 136 PDAC patients who received neoadjuvant therapy and pancreaticoduodenectomy. The results were correlated with clinicopathological parameters and survival.Results: High CD4+TILs in treated PDAC were associated with high CD8+TILs (P= 0.003), differentiation (P= 0.04), and a lower frequency of recurrence (P= 0.02). Patients with high CD4+TILs had longer disease-free survival and overall survival (OS) than did patients with low CD4+TILs (P< 0.01). The median OS of patients with a high CD8+/FOXP3+lymphocyte ratio (39.5 [standard deviation, 6.1] months) was longer than that of patients with a low CD8+/FOXP3+lymphocyte ratio (28.3 [standard deviation, 2.3] months;P= 0.01). In multivariate analysis, high CD4+TILs were an independent prognostic factor for disease-free survival (hazard ratio, 0.49; 95% confidence interval, 0.30–0.81;P= 0.005) and OS (hazard ratio, 0.54; 95% confidence interval, 0.33–0.89;P= 0.02).Conclusions: High level of CD4+lymphocytes is associated with tumor differentiation and lower recurrence and is an independent prognostic factor for survival in PDAC patients treated with neoadjuvant therapy.